Department of Endocrinology, Punan Hospital of Pudong New District, Shanghai, China.
Hangzhou Aeronautical Sanatorium of China Air Force, Hangzhou, China.
Obes Facts. 2022;15(2):180-185. doi: 10.1159/000520711. Epub 2021 Dec 30.
Apart from their recognized lipid-lowering effect, Hedan tablets, a mixture of Chinese herbal medicines, have demonstrated a certain weight-loss effect in clinical practice. The aim of this randomized, double-blind, placebo-controlled study was to verify the effect of Hedan tablets on body weight (BW) and insulin resistance (IR) in patients with metabolic syndrome (MetS).
A total of 62 eligible patients with MetS were divided into two groups: the treatment group (Hedan tablets at 4.38 g/day tid) and the control group (placebo treatment). Both groups attended follow-ups at 8, 16, and 24 weeks during the process. The parameters of the assessment include lipid level, BW, triglyceride (TG) to high-density lipoprotein cholesterol (HDLc) ratio (TG/HDLc), homeostasis model assessment for IR (HOMA-IR) index, and adiponectin.
Patients in the treatment group showed a significant decrease in BW compared to those in the control group (-4.47 vs. 0.06 kg) after 8 weeks of treatment. A significant decrease in body mass index (BMI) was also observed in the treatment group after 16 weeks of treatment (-1.79 vs. -0.03 kg/m2). In the treatment group, 20 out of 31 (64.5%) patients lost 5-10% BW and 4 out of 31 (12.9%) patients lost over 10% BW after 24 weeks of treatment. Although there were no significant changes in the patients' HOMA-IR, the treatment group showed a significant reduction in TG/HDLc (-0.98 vs. -0.19) after 8 weeks of treatment and a significant increase in adiponectin (6.87 vs. -0.43) after 16 weeks of treatment.
DISCUSSION/CONCLUSION: The Hedan tablets significantly improve BW, BMI, TG/HDLc, and adiponectin in patients with MetS. Thus, Hedan tablets may be used as an adjunct to existing MetS management methods.
除了公认的降脂作用外，和丹片（一种中草药混合物）在临床实践中已显示出一定的减肥效果。本项随机、双盲、安慰剂对照研究的目的是验证和丹片对代谢综合征（MetS）患者体重（BW）和胰岛素抵抗（IR）的影响。
共有 62 名符合条件的 MetS 患者被分为两组：治疗组（和丹片，4.38g/天，tid）和对照组（安慰剂治疗）。两组均在 8、16 和 24 周进行随访。评估参数包括血脂水平、BW、甘油三酯（TG）与高密度脂蛋白胆固醇（HDLc）比值（TG/HDLc）、胰岛素抵抗评估的稳态模型（HOMA-IR）指数和脂联素。
治疗 8 周后，治疗组患者的 BW 与对照组相比明显下降（-4.47 比 0.06kg）。治疗 16 周后，治疗组患者的 BMI 也明显下降（-1.79 比-0.03kg/m2）。在治疗组中，31 名患者中有 20 名（64.5%）体重减轻了 5-10%，31 名患者中有 4 名（12.9%）体重减轻了 10%以上，24 周后。尽管患者的 HOMA-IR 没有显著变化，但治疗组在治疗 8 周后 TG/HDLc 显著降低（-0.98 比-0.19），16 周后脂联素显著增加（6.87 比-0.43）。
讨论/结论：和丹片可显著改善 MetS 患者的 BW、BMI、TG/HDLc 和脂联素。因此，和丹片可作为 MetS 现有治疗方法的辅助手段。
